Drug Trial Radar · NCT07047989
NWRD09 for HPV-16 Related Cervical HSIL
Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Jul 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Newish Biotech (Wuxi) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).
Conditions
- High-grade Squamous Intraepithelial Lesion (HSIL)
Interventions
NWRD09 injectionBiological
NWRD09 administered by intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: To week 24
- Dose-limiting toxicity (DLT)Time frame: Within 28 days of the third dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.